Elicera Therapeutics' CSO invited to present at multiple scientific conferences
Gothenburg, January 22, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company's Chief Scientific Officer, professor Magnus Essand, has been invited to hold presentations on CAR T-cells and the iTANK-platform at multiple scientific conferences.
EBMT-EHA 8th European CAR T-cell Meeting, 12-14 February 2026
Palma de Mallorca, Spain
Title of presentation: NAP CAR T cells for solid tumors
https://www.ebmt.org/events/ebmt-eha-8th-european-car-t-cell-meeting
10th Zurich Immuno-Oncology Conference 2026, 6 March 2026
Zürich, Switzerland
Title of presentation: Optimising CAR-T cells for improved efficacy and reduced toxicity
https://www.usz.ch/en/event/10th-zurich-immuno-oncology-conference-2026/
Onkologidagarna, 17-19 March 2026
Gothenburg, Sweden
Paneldiskussion: Framtidens terapier
https://onkologidagarna.se